Influence of the i/d polymorphism of the angiotensin-converting enzyme gene on the outcome of microalbuminuria in essential hypertension by Redón i Más, Josep et al.
ISSN: 1524-4563 
Copyright © 2000 American Heart Association. All rights reserved. Print ISSN: 0194-911X. Online
72514
Hypertension is published by the American Heart Association. 7272 Greenville Avenue, Dallas, TX
 2000;35;490-495 Hypertension
Rovira, Maria Eugenia Armengod and Richard S. Cooper 
Josep Redon, Felipe Javier Chaves, Youlian Liao, Jose Maria Pascual, Eduardo
 on the Outcome of Microalbuminuria in Essential Hypertension
Influence of the I/D Polymorphism of the Angiotensin-Converting Enzyme Gene
 http://hyper.ahajournals.org/cgi/content/full/35/1/490
located on the World Wide Web at: 
The online version of this article, along with updated information and services, is
 http://www.lww.com/reprints




Fax:Kluwer Health, 351 West Camden Street, Baltimore, MD 21202-2436. Phone: 410-528-4050. 
Permissions: Permissions & Rights Desk, Lippincott Williams & Wilkins, a division of Wolters
  
 http://hyper.ahajournals.org/subscriptions/
Subscriptions: Information about subscribing to Hypertension is online at 
 at SWETS SUBS SERV-#54225388 on May 18, 2010 hyper.ahajournals.orgDownloaded from 
Influence of the I/D Polymorphism of the
Angiotensin-Converting Enzyme Gene on the Outcome of
Microalbuminuria in Essential Hypertension
Josep Redon, Felipe Javier Chaves, Youlian Liao, Jose Maria Pascual, Eduardo Rovira,
Maria Eugenia Armengod, Richard S. Cooper
Abstract—The objective of the present study was to analyze the influence of the I/D polymorphism of the ACE gene on
the outcome of microalbuminuria in essential hypertensive patients who were receiving antihypertensive treatment. One
hundred thirty-six essential hypertensive patients who were ,50 years old and had never previously received treatment
with antihypertensive drugs were included in the study. During a 3-year period, patients received nonpharmacological
treatment consisting of moderate salt restriction and a low-calorie diet they were obese, with or without a regimen of
antihypertensive drugs based on b-blockers or ACE inhibitors. Hydrochlorothiazide was added when necessary to
maintain the blood pressure goal of ,135/85 mm Hg. At the beginning of the study and at yearly intervals, systolic and
diastolic blood pressures (SBP and DBP, respectively), 24-hour urinary albumin excretion (UAE), renal function, and
biochemical profile measurements were made. The insertion/deletion (I/D) polymorphism of the ACE gene was
determined through the use of polymerase chain reaction. The variables used in the statistical analysis were the
measurements at the start of the study and the increase or decrease detected during the follow-up, estimated as individual
specific regression line slope values. At baseline, no differences in blood pressure or UAE values were observed among
genotypes. Likewise, the genotype or allele frequency was not significantly different between normoalbuminurics and
microalbuminurics. After the 3 treatment years, significant reductions in SBP, DBP, and UAE were found (SBP
151.6617.3 reduced to 137.2614.3 mm Hg, P,0.001; DBP 96.668.9 reduced to 84.569.8 mm Hg, P,0.001; UAE
36.7671.5 reduced to 28.3678.6 mg/24 h, P,0.05). The slopes of these parameters over time did not differ
significantly among genotypes. The slope of SBP was the main factor related to the slope of logUAE (P,0.003). A
significant positive correlation coefficient between the SBP and logUAE slopes was observed for the DD patients
(r50.57, P,0.0001) but was absent in patients carrying the I allele (II r520.03, P5NS; I/D r50.01, P5NS).
Follow-up studies should be used to achieve a better understanding of the impact of candidate gene polymorphisms on
the development of hypertension-induced organ damage. Assessment of the I/D polymorphism of the ACE gene may
identify subjects who require a greatly lowered blood pressure to prevent organ damage and to reduce hypertension-
associated complications and death. (Hypertension. 2000;35[part 2]:490-495.)
Key Words: hypertension, essential n albuminuria n genetics n angiotensin-converting enzyme gene
Microalbuminuria has attracted attention as an earlymarker of organ damage in hypertension, and prelim-
inary data that support microalbuminuria as a prognostic
factor for cardiovascular or renal risk in hypertension have
recently been published.1 Previous studies by our group and
by others have demonstrated that in essential hypertension,
microalbuminuria is related to blood pressure (BP) values2,3
and to the presence of hyperinsulinemia,4,5 as an expression
of insulin resistance.5 Blood pressure and hyperinsulinemia,
however, account for only part of the variation in microalbu-
minuria among hypertensives.4 Some studies that support the
contribution of genetic background to the development of
microalbuminuria in hypertension have recently been
published.6–8
The D allele of the polymorphism insertion/deletion (I/D) of
the ACE gene, involving an intronic deletion (D) of a 287-bp
sequence, has been linked to a higher prevalence of microalbu-
minuria6,8 and to nephroangiosclerosis8 among hypertensives. In
other diseases that affect the kidney, such as diabetes or IgA
nephropathy, subjects carrying the D allele also have the highest
risk of the development of renal failure.9,10 Furthermore, the D
allele has been linked to a failure of the renoprotective action of
ACE inhibitors (ACEIs) to retard the development of end-stage
renal disease.11,12
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The influence of the I/D polymorphism on the outcome of
microalbuminuria has not been explored in essential hyper-
tension, and the objective of the present study was to analyze
this relationship in patients receiving antihypertensive treat-
ment during a 3-year follow-up period. The primary purpose
of this study was to obtain information on the impact of the
I/D polymorphism on the development of microalbuminuria
in essential hypertension.
Methods
Selection of Study Participants and Design
Patients included in the study were selected from an outpatient clinic
over the 5-year period of January 1990 through December 1994. All
patients who fulfilled the inclusion criteria were invited to partici-
pate, and written consent was requested. The inclusion criteria
included (1) diastolic BP (DBP) in the range of high normal to
moderate essential hypertension, defined as being between 90 and
114 mm Hg (Korotkoff phase V, sitting position) for 3 visits at
1-month intervals; (2) age of 25 to 50 years; (3) the absence of
cardiovascular events; (4) a glomerular filtration rate of .60 mL z
min21 z 1.73 m22; and (5) no previous treatment for hypertension.
Patients with nephropathy, diabetes mellitus, urinary tract infection,
fasting glucose in serum of .120 mg/dL, or a positive dipstick for
albumin or glucose were excluded. A total of 146 patients were
included in the study. The study was approved by the Ethical
Committee of the Hospital of Sagunto, and all patients granted their
consent in writing.
After enrollment, and according to clinical criteria, which did not
consider microalbuminuria, the patients were placed on a nonphar-
macological treatment that consisted of moderate salt restriction and
a low-calorie diet, if overweight, with or without a regimen of
antihypertensive drugs based on b-blockers or ACEIs. Hydrochlo-
rothiazide was added when necessary to maintain the BP goal of
,135/85 mm Hg. Of the initial 146 patients, 136 completed the
3-year study. Twenty-three received only the nonpharmacological
treatment, 29 received b-blockers, 59 received ACEIs, and the
remaining 25 had their treatment shifted over time due to a variety of
reasons. During the 3 years of follow-up, urinary albumin excretion
(UAE), renal function, and other parameters were assessed on a
yearly basis.
Clinical and Analytical Procedures
All patients underwent a complete clinical work-up to rule out
secondary hypertension. Blood pressure was measured in a quiet
environment with the use of a mercury sphygmomanometer with the
patient in a sitting position after 5 minutes of rest, according to the
recommendations of the British Hypertension Society. Systolic BP
(SBP) and DBP were measured according to Korotkoff phases I and
V, respectively.
Blood samples were obtained in the mornings after that partici-
pants had fasted for a minimum of 8 hours. Serum biochemical
profiles and lipids were measured with an autoanalyzer SMAC. The
glomerular filtration rate was estimated on the basis of the clearance
of endogenous creatinine as expressed in reference to body surface
(mL z min21 z 1.73 m22).
UAE for 2 separate 24-hour urine collections was measured with
the use of an immunonephelometric assay (Behring Institute).
Aliquots of urine were taken during a 24-hour period, stored in glass
tubes at 4°C, and analyzed 1 to 7 days after collection. For each
patient, the UAE was considered the mean of values obtained for the
2 separate 24-hour urine collections. If a difference in values
obtained for the 2 samples was .25% of the higher value or of a
creatinine excretion value during a 24-hour period was lower than
expected for body size and gender, a third sample was requested. On
the basis of UAE, hypertensive patients were classified as normoal-
buminuric (UAE ,30 mg/24 h) or microalbuminuric (UAE 30 to
300 mg/24 h).
I/D Polymorphism of ACE Gene
Genomic DNA was extracted from blood according to the procedure
of Tilzer et al.13 Genotyping of ACE I/D was assayed with the use of
DNA amplification with the oligonucleotides described by Rigat et
al.14 Reactions were performed in a final volume of 15 mL contain-
ing 0.75 mmol/L concentration of each primer, 2 ng/mL DNA,
75 mmol/L concentration of each dNTP, 1.5 mmol/L MgCl2,
75 mmol/L Tris z HCl (pH 9.0), 5 mmol/L KCl, 20 mmol/L
(NH4)2SO2, and 0.02 U/mL Netzyme ADN polymerase (Need, SL).
The DNA was amplified for 40 cycles with denaturation at 94°C for
30 seconds and extension at 72°C for 90 seconds (PTC-100 thermal
cycler; M.I. Research). DNA sequencing confirmed that no mistyp-
ing of I/C heterozygotes occurred under these conditions. The
polymerase chain reaction products were separated through 2%
agarose gel electrophoresis, and DNA was visualized with ethidium
bromide staining (Figure 1).
Statistical Analysis
For each variable, the values were expressed as mean6SD values.
Data on UAE were analyzed in 2 ways. First, the UAE data were
categorized into normoalbuminuric and microalbuminuric groups, as
previously defined, and second, a continuous variable with logarith-
mic transformation (logUAE) was used. The variables used in the
statistical analysis were the values of BP, UAE, and biochemical
Figure 1. Values of SBP, DBP, and UAE at baseline and yearly
during follow-up in 3 genotypes of I/D polymorphism of ACE
gene (II n522, I/D n559, and DD n555).
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profile at the beginning of the study. The changes of parameters
during the follow-up were estimated as the individual-specific
regression line slope values. The type of treatment was included
as nonpharmacological treatment (0), b-blockers (1), and ACEIs
(2). One-way ANOVA and Kruskal-Wallis and Fisher tests were
used to compare the parameters between patients with and
without microalbuminuria and among patients with different
genotypes. Multiple regression analysis was performed to assess
the factors related to the changes in UAE during the follow-up
and the influence of genotypes. Logistic regression analyses were
performed to assess the influence of genotype on the presence
of microalbuminuria. Values of P,0.05 were considered
statistically significant.
Results
General Characteristics of the Study Population
The general characteristics, BP values, renal function, and
UAE of the patients in each genotype of the I/D poly-
morphism who completed the study are shown in Table 1.
Genotypes of the I/D polymorphism of the ACE gene were
in Hardy-Weinberg equilibrium. No significant differences
were observed in terms of age, body mass index, UAE, or
SBP and DBP. Gender was the only characteristic that
differed among the genotypes, with a predominance of
women carrying the D allele. At the beginning of the study,




Genotype distribution and allele frequencies of both poly-
morphisms in the initially normoalbuminurics and microal-
buminurics are given in Table 2. No differences in the
presence of microalbuminuria were observed among the
genotypes of the I/D polymorphism. The allele frequencies
also were not significantly different between the normoalbu-
minurics and microalbuminurics. Genotypes did not influence
the presence of microalbuminuria when age, gender, and BP
were taken into account in a logistic regression model (data
not shown).
From the 41 initially microalbuminurics, 26 became nor-
moalbuminurics during the 3 years of antihypertensive treat-
ment. There were no significantly differences in the normal-
ization rates of microalbuminuria across the genotypes. From
the 95 initially normoalbuminurics, 7 became microalbu-
minurics despite the antihypertensive treatment. Although
with this small number it was not possible to observe whether
the genotype influenced the occurrence rates, all subjects who
developed microalbuminuria had the D allele: 5 homozygotes
(DD genotype) and 2 heterozygotes (I/D genotype). The
prevalence of the D allele increases from 0.57 at the begin-
ning until 0.68 after the 3-year follow-up in the subjects who
were microalbuminurics.
TABLE 1. General Characteristics, Blood Pressure Values,
Urinary Albumin Excretion, and the Slope of the Regression
Lines Over Time, Grouped by Genotype of the I/D Polymorphism
of the ACE Gene
II (n522) I/D (n559) DD (n555)
Age, y 39.767.6 38.668.1 41.267.3
Gender, M/F 16/6 32/27 23/32
Body mass index, kg/m2 28.264.2 27.964.0 28.964.7
UAE.30 mg/24 h, n (%) 9 (41) 17 (29) 15 (27)
Baseline
SBP, mm Hg 150.1612.8 151.3620.6 152.4615.0
DBP, mm Hg 98.368.7 96.069.3 96.668.7
UAE, mg/24 h 34.4647.1 29.4651.5 45.4694.6
Follow-up
Slope SBP, mm Hg 25.7665.22 23.9965.61 24.1166.12
Slope DBP, mm Hg 25.6164.34 23.5563.31 23.5463.92
Slope UAE, mg/24 h 22.87610.8 22.58611.7 21.29615.1
Antihypertensive treatment
Nonpharmacological 1 13 9
b-Blockers 4 14 11
ACEI 11 23 25
Others 6 8 11
Nonpharmacological indicates restriction of salt, calories, or both on the
basis of dietary advice; b-blockers, atenolol or bisoprolol only; ACEIs, enalapril
or lisinopril only; others, shifted treatments.
TABLE 2. Genotype and Allele Frequencies of I/D Polymorphism of the ACE
Gene: Normoalbuminuric Versus Microalbuminuric Patients
UAE Status
Genotype Allele
II I/D DD I D
Baseline
Normoalbuminurics 13 42 40 0.36 0.64
Microalbuminurics 9 17 15 0.43 0.57
Pearson’s x2 (P value) x251.48 (0.48) x251.03 (0.31)
After 3 y
Normoalbuminurics 20 50 45 0.39 0.61
Microalbuminurics 2 9 10 0.32 0.68
Pearson’s x2 (P value) x250.69 (0.71) x251.07 (0.30)
Became normoalbuminurics 7 10 9 0.44 0.56
New microalbuminurics 0 2 5 0.14 0.86
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I/D Polymorphism Genotypes, Blood Pressure,
and UAE
The values of BP and UAE at the beginning and the changes
throughout the study in patients with the different genotypes
of I/D polymorphism are shown in Figure 1. At baseline, no
differences in BP values were observed among the genotypes,
and although UAE has the highest value in DD subjects,
differences did not achieve statistical significance.
After the 3 treatment years, significant reductions in SBP,
DBP, and UAE were noted (SBP 151.6617.3 to 137.26
14.3 mm Hg, P,0.001; DBP 96.668.9 to 84.569.8 mm Hg,
P,0.001; UAE 36.7671.5 to 28.3678.6 mg/24 h, P,0.05).
Values of SBP, DBP, and UAE, as well as the slopes of these
parameters over time, did not differ significantly among
genotypes (Table 1).
We analyzed the factors related with the changes in UAE
by using multiple regression analysis. The slope of SBP was
the main factor related to the slope of logUAE (P,0.003),
accounting for 7% of the variance. Neither gender, DBP,
weight, glucose slopes, type of treatment, nor genotype
influenced the changes in logUAE. The relationship between
the SBP and logUAE slopes, however, strongly differed
among the genotypes (Figure 2). A significant positive
correlation coefficient was observed for the DD patients
(r50.57, P,0.0001) that was not present for the II (r520.03,
P5NS) and I/D (r50.01, P5NS) patients.
The same analysis was performed for the 59 subjects
treated with ACEIs. The relationship between the SBP and
logUAE slopes remained significant for the subjects with DD
genotype (r50.78, P,0.001) and not for those with the II
(r0.06, P5NS) or I/D (r50.21, P5NS) genotype or for
subjects carrying the I allele (both II and I/D) (r50.08,
P5NS).
Discussion
Patients with essential hypertension are heterogeneous in
their clinical characteristics and prognosis. Factors influenc-
ing the variable prevalence of end-organ damage and the
prognosis in patients with hypertension of similar severity are
not well understood. Genetic background seems to be one of
the main determinants of the heterogeneity, and a search for
candidate genes has been initiated in the past few years. In the
present study, homozygotes for the D allele of the I/D
polymorphism of the ACE gene showed a strong positive
relationship between changes in SBP and UAE, something
that was not observed in patients carrying the I allele. This
positive correlation was also observed for patients treated
with ACEIs.
We studied the influence of I/D polymorphism in the UAE
of essential hypertensives by observing its impact on the
outcome of microalbuminuria during antihypertensive treat-
ment. This approach allowed us to consider the impact of
genetics on the development of microalbuminuria, offering
information complementary to that of association studies.6–8
To reduce potential confounding factors, we included hyper-
tensives with selected characteristics: adults ,50 years old
who were never previously treated with antihypertensive
drugs and in whom diabetes mellitus and nephropathy had
been excluded. To reduce day-to-day variability, UAE was
measured in 2 separate 24-hour samples.
Another potential confounding factor, the type of the
antihypertensive treatment that was used, merits special
comment. Several studies have demonstrated that a reduction
in BP values with the use of antihypertensive drugs was
accompanied by a decrease in microalbuminuria in propor-
tion to the reduction in BP. ACEIs and antagonists of the
angiotensin II type 1 receptor have additional beneficial
effects on microalbuminuria, independent of BP reduction.15
In the present study, the outcome of microalbuminuria was
related to the SBP achieved throughout the 3 years of
antihypertensive treatment, which is in agreement with pre-
vious studies. The changes in UAE values, however, were
lower than those previously reported during short periods of
observation,16,17 when only the changes in BP values and the
effect of the drug itself influenced it. A longer observation
period, such as the present 3-year study, allows us to analyze
not only the effect of the changes in BP but also the impact
of other factors on the UAE.
The significance of microalbuminuria in essential hyper-
tension is much broader than expected, and there are several
main factors that determine the presence of microalbumin-
uria.15 Blood pressure level has been considered the most
important factor related to microalbuminuria in essential
hypertension, supported by the higher prevalence of microal-
buminuria in patients with severe hypertension and by a
positive relationship between UAE and BP values.3,18 Fur-
thermore, elevated ambulatory BP values and their persis-
tence during sleep have been associated with the presence of
microalbuminuria in essential hypertension.19
Beside BP values, the overactivity of the renin-angiotensin
system (RAS) and insulin resistance have been linked to the
development of microalbuminuria. Among essential hyper-
tensives, microalbuminurics have higher renal vascular resis-
tance than normoalbuminurics despite similar BP levels, and
a higher activated RAS was observed in young patients with
essential hypertension who had albuminuria than was in those
who did not.20 Hyperinsulinemia, as an expression of insulin
resistance, also has been related to microalbuminuria in
hypertensive subjects.4,5 Higher peripheral resistance to the
action of insulin, as estimated with as euglycemic clamp, has
Figure 2. Regression lines and their corresponding 95% confi-
dence interval between SBP and logUAE slope values in sub-
jects who are homozygotes for D allele (DD genotype) and in
those carrying I allele (II plus I/D genotypes).
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been observed in microalbuminuric patients but not in nor-
moalbuminurics in essential hypertension.5,21
The impact of the I/D polymorphism on BP levels, RAS
activation, and insulin resistance was reported recently. Al-
though the I/D polymorphism seems to not influence BP
values,22 the presence of the D allele has been linked to higher
levels of renal damage among hypertensives. Our group
observed a significant relationship between 24-hour ambula-
tory BP and UAE in essential hypertensives carrying the DD
genotype, a relationship that was not observed for the II or
I/D genotypes.23 Higher ACE plasma levels, as well as higher
local ACE activity, as described for subjects with the D allele,
have been advocated to account for the highest rate of
end-organ damage associated with this genotype.24 The in-
creased activity of ACE leads to higher local levels of
angiotensin II, a peptide that produces vasoconstriction,
aldosterone release, sodium and water retention, and cellular
growth.25
In contrast, in hypertensives carrying the I allele, higher
rates of insulin resistance and hyperinsulinemia have been
reported.26,27 Although no plausible explanation has been
offered until now, recent evidence suggests a tight connection
between insulin resistance and RAS. Angiotensin II infusion
into normotensive volunteers has been shown to improve
insulin resistance on the basis of hemodynamics through a
redistribution of blood flow in skeletal muscle and on the
basis of nonhemodynamic mechanisms.28 It is conceivable
that the slightly reduced ACE expression in ACE I allele
carriers is associated with reduced insulin sensitivity.
Whether the association between the I allele and insulin
resistance is dependent on a lower RAS activation or is
dependent on functional polymorphisms of another gene in
linkage disequilibrium with the ACE gene is not fully
understood. Among the genes located near the ACE locus in
the 17q23 chromosome are members of the human growth
hormone family that can influence glucose metabolism.
The most relevant observation in the present study was the
relationship between changes in BP and changes in UAE,
which was observed only in subjects who were homozygotes
for the D allele. In accordance with this, the higher the SBP
reduction, the higher was the UAE fall in the DD genotype,
and consequently, better renal and vascular protection could
be achieved. The relationship between BP values and mi-
croalbuminuria observed in our previous study23 and in the
present study in subjects who were homozygotes for the D
allele might explain the association between genotypes of the
I/D polymorphism and either RAS activation or insulin
resistance. In subjects carrying the I allele, among whom the
highest reduction in microalbuminuria was observed, UAE
may be more dependent on the presence of insulin resistance
or on other unknown factors and, consequently, less influ-
enced by BP reduction than in subjects who are homozygotes
for the D allele.
A reduction in BP values29 and the administration of
ACEIs30 are 2 of the main ways to decrease or retard the
progression of renal damage toward end-stage renal disease.
According to previous studies, subjects with the DD geno-
type, however, seem to show the highest risk of developing
renal damage and the poorest renal function outcome during
treatment.11,12 Whether further BP reduction is necessary to
improve renal protection in subjects with DD genotype is an
attractive hypothesis to be tested.
Finally, another aspect of the results deserve further com-
ment. At the beginning, no differences in the prevalence of
microalbuminuria were observed among patients with the
genotypes of the I/D polymorphism. In contrast, the fre-
quency of the D allele increases in the patients who were
microalbuminuric after the treatment, limiting the occurrence
of microalbuminuria to patients with the D allele. Moreover,
subjects carrying II genotype achieved the highest reduction
rate in microalbuminuria. This observation may help us
understand the association between the D allele and microal-
buminuria or renal damage previously reported in hyperten-
sives.6,8 If patients who had previously received antihyper-
tensive treatment were included in the study, a treatment-
induced bias may be present, increasing the presence of the D
allele among patients with the highest UAE or the poorest
renal function.
In conclusion, follow-up studies may be useful to obtain a
better understanding of the relationship between candidate
gene polymorphisms and the development of hypertension-
induced organ damage. An assessment of the I/D poly-
morphism of the ACE gene may identify subjects who require
a large reduction in BP to protect organs from damage and to
reduce hypertension-associated complications and death.
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